Gender effect on metformin and sitagliptin [Regulatives / Guidelines]

posted by dshah  – India/United Kingdom, 2022-03-01 14:01 (779 d 20:10 ago) – Posting: # 22818
Views: 1,231

Dear Khageswara Rao!
As per label for metformin: Metformin pharmacokinetic parameters did not differ significantly between normal subjects and patients with type 2 diabetes when analyzed according to gender (males = 19, females = 16). Similarly, in controlled clinical studies in patients with type 2 diabetes, the antihyperglycemic effect of metformin hydrochloride tablets, USP was comparable in males and females.

For Sitagliptin: Based on a population pharmacokinetic analysis or a composite analysis of available pharmacokinetic data, BMI, gender, and race do not have a clinically meaningful effect on the pharmacokinetics of sitagliptin. When the effects of age on renal function are taken into account, age alone did not have a clinically meaningful impact on the pharmacokinetics of sitagliptin based on a population pharmacokinetic analysis. Elderly subjects (65 to 80 years) had approximately 19% higher plasma concentrations of sitagliptin compared to younger subjects.
Kindly find the screenshot for same:
Thus, gender effect is not anticipated and inclusion of only male subject should not have clinical significance on outcome of study.
Divyen Shah

Complete thread:

UA Flag
 Admin contact
22,987 posts in 4,824 threads, 1,663 registered users;
78 visitors (0 registered, 78 guests [including 7 identified bots]).
Forum time: 11:11 CEST (Europe/Vienna)

The only way to comprehend what mathematicians mean by Infinity
is to contemplate the extent of human stupidity.    Voltaire

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz